Johnson & Johnson's ICOTYDE meets primary endpoint in Phase 3 psoriatic arthritis trial

• Johnson & Johnson reported positive Phase 3 results for once-daily oral ICOTYDE in biologic-naive adults with active psoriatic arthritis.
• The trial met its primary endpoint, showing significant improvement in joint disease activity versus placebo at Week 16.
• Joint and skin responses improved further through Week 24, with no new safety signals identified.
• Results are being presented at the American College of Rheumatology Convergence 2026.
• ICOTYDE already treats plaque psoriasis in the U.S. but is not approved for psoriatic arthritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611071003PR_NEWS_USPR_____NY91565) on November 07, 2026, and is solely responsible for the information contained therein.